The following article is part of conference coverage from the 2018 American Academy of Dermatology Annual Meeting in San Diego, California. Dermatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in dermatology. Check back for the latest news from AAD 2018.

Oral ivermectin and oral fluralaner are equally effective in patients with scabies, according to the results of a double-blind clinical trial presented at the 2018 American Academy of Dermatology Annual Meeting, February 16-20, 2018 in San Diego, California.

Mohamad Goldust, MD, and colleagues evaluated the efficacy of both treatments by randomly assigning 242 patients with scabies to either a single dose of 200 µg/kg body weight oral ivermectin or a single dose of oral fluralaner. Treatment response was assessed at weeks 2 and 4 with another round of treatment given after week 2 if the initial treatment failed.


Continue Reading

Participants in the ivermectin group experienced a cure rate of 67.7% at week 2, which increased to 82.6% at week 4. Participants in the fluralaner group experienced a cure rate of 71.5% at week 2, which increased to 85.9% at week 4.

Oral ivermectin and oral fluralaner had similar outcomes in patients with scabies 4 weeks after treatment, though oral fluralaner had slightly better results. Researchers also noted that fluralaner is a more cost-effective option and that the treatment can be given with “better compliance with or without supervision.”

For more coverage of AAD 2018, click here.

Reference

Goldust M, et al. Oral ivermectin vs. oral fluralaner for the treatment of scabies. Presented at: 2018 American Academy of Dermatology Annual Meeting. February 16-20, 2018; San Diego, CA. Abstract 6533.